{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:49:03Z","timestamp":1791676143486,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07549-x","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:41:28Z","timestamp":1791661288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous efficacy and safety of fluocinolone acetonide implant: long-term insights in diabetic macular edema patients from a portuguese hospital"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4949-7937","authenticated-orcid":false,"given":"Daniela Figueiredo","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-5128","authenticated-orcid":false,"given":"Andr\u00e9","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-5682","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Caiado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-3618","authenticated-orcid":false,"given":"Nuno","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-6692","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Men\u00e9res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1561","authenticated-orcid":false,"given":"Bernardete","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"5","key":"7549_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40265-017-0704-6","volume":"77","author":"SU Shah","year":"2017","unstructured":"Shah SU, Maturi RK (2017) Therapeutic Options in Refractory Diabetic Macular Oedema. Drugs 77(5):481\u2013492","journal-title":"Drugs"},{"key":"7549_CR2","doi-asserted-by":"crossref","unstructured":"Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A et al (2018) Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research, vol 63. Elsevier Ltd, pp 20\u201368","DOI":"10.1016\/j.preteyeres.2017.10.006"},{"key":"7549_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000516614","volume":"244","author":"DAK Kuroiwa","year":"2021","unstructured":"Kuroiwa DAK, Malerbi FK, Regatieri CVS, S. Karger AG (2021) New insights in resistant diabetic macular edema. Ophthalmologica 244:485\u2013494","journal-title":"Ophthalmologica"},{"key":"7549_CR4","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D et al (2022) Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications, MDPI. Cells 11","DOI":"10.3390\/cells11213362"},{"key":"7549_CR5","doi-asserted-by":"crossref","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Karger AG et al (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica S 237:185\u2013222","DOI":"10.1159\/000458539"},{"key":"7549_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ et al (2016) Early and Long-Term Responses to Anti\u2013Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol 172:72\u201379","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"7549_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL et al (2016) Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134(3):278\u2013285","journal-title":"JAMA Ophthalmol"},{"key":"7549_CR8","doi-asserted-by":"crossref","unstructured":"Kwon J, Jee D (2018) Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment. PLoS ONE 13(9)","DOI":"10.1371\/journal.pone.0203408"},{"issue":"8","key":"7549_CR9","first-page":"2449","volume":"260","author":"B Pessoa","year":"2022","unstructured":"Pessoa B, Heitor J, Coelho C, Leander M, Men\u00e9res P, Figueira J et al (2022) Systemic and vitreous biomarkers \u2014 new insights in diabetic retinopathy. Graefe\u2019s Archive Clin Experimental Ophthalmol 260(8):2449\u20132460","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"3","key":"7549_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M et al (2013) Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 120(3):583\u2013587","journal-title":"Ophthalmology"},{"issue":"10","key":"7549_CR11","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J et al (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119(10):2125\u20132132","journal-title":"Ophthalmology"},{"key":"7549_CR12","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG et al (2011) Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 118(4)","DOI":"10.1016\/j.ophtha.2010.12.028"},{"issue":"2","key":"7549_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","volume":"30","author":"AJ Augustin","year":"2020","unstructured":"Augustin AJ, Bopp S, Fechner M, Holz F, Sandner D, Winkgen AM et al (2020) Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN\u00ae (0.19\u00a0mg fluocinolone acetonide implant). Eur J Ophthalmol 30(2):382\u2013391","journal-title":"Eur J Ophthalmol"},{"key":"7549_CR14","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.2147\/OPTH.S283561","volume":"15","author":"B Mushtaq","year":"2021","unstructured":"Mushtaq B, Bhatnagar A, Palmer H (2021) Real-world outcomes in diabetic Macular Edema for the 0.2 \u00b5g\/day fluocinolone acetonide implant: Case series from the Midlands, UK. Clin Ophthalmol 15:2935\u20132943","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"7549_CR15","first-page":"1012","volume":"36","author":"C Bailey","year":"2022","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J (2022) Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye (Basingstoke) 36(5):1012\u20131018","journal-title":"Eye (Basingstoke)"},{"issue":"6","key":"7549_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","volume":"129","author":"MA Singer","year":"2022","unstructured":"Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH (2022) Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology 129(6):605\u2013613","journal-title":"Ophthalmology"},{"key":"7549_CR17","doi-asserted-by":"crossref","unstructured":"Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A et al (2022) Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study. Pharmaceutics 14(4)","DOI":"10.3390\/pharmaceutics14040723"},{"key":"7549_CR18","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bjo-2022-321415","volume":"107","author":"R Khoramnia","year":"2023","unstructured":"Khoramnia R, Peto T, Koch F, Taylor SR, Castro De Sousa JP, Hill L et al (2023) Clinical science Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol 107:1502\u20131508","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"7549_CR19","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1007\/s10792-023-02864-2","volume":"43","author":"JM Ruiz-Moreno","year":"2023","unstructured":"Ruiz-Moreno JM, Ad\u00e1n A, Lafuente M, Asencio Dur\u00e1n M, Arias Barquet L, Garc\u00eda Layana A et al (2023) Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study. Int Ophthalmol 43(12):4639\u20134649","journal-title":"Int Ophthalmol"},{"key":"7549_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/OPTH.S382920","volume":"18","author":"RM Soares","year":"2024","unstructured":"Soares RM, Ferreira CC, Fernandes JdaS, Madeira C, Silva LMA, Saraiva E et al (2024) Real-World Evidence of the Long-Term Effectiveness of 0.2 \u00b5g\/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema \u2013 A Single Center Study. Clin Ophthalmol 18:1057\u20131066","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"7549_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40123-026-01339-8","volume":"15","author":"Y Serrar","year":"2026","unstructured":"Serrar Y, Sejournet L, Allignet B, Bounetta S, Deiri M, Gullon C et al (2026) Prevalence and Risk Factors of Ocular Hypertension Following Fluocinolone Acetonide (Iluvien\u00ae) Intravitreal Injections: The SAFAC Study. Ophthalmol Ther 15(4):1341\u20131353","journal-title":"Ophthalmol Ther"},{"key":"7549_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13010072","volume":"13","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Baillif S, Creuzot-Garcher C, Delyfer MN, Matonti F, Weber M, MDPI AG (2021) Real-world efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: A systematic review. Pharmaceutics 13:1\u201314","journal-title":"Pharmaceutics"},{"key":"7549_CR23","first-page":"437","volume":"13","author":"B Pessoa","year":"2020","unstructured":"Pessoa B, Melo-Beir\u00e3o J, Meireles A, Men\u00e9res P (2020) Supplemental therapy with intravitreal ranibizumab therapy following treatment of diabetic macular edema with the 0.19\u00a0mg fluocinolone acetonide implant (ILUVIEN\u00ae). Int Med Case Rep J 13:437\u2013448","journal-title":"Int Med Case Rep J"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07549-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07549-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07549-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:07:04Z","timestamp":1791673624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07549-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":23,"alternative-id":["7549"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07549-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol received approval from the Ethics Committee of the Unidade Local de Sa\u00fade (ULS) Santo Ant\u00f3nio (Porto, Portugal), which waived the requirement for informed consent to conduct the study. All participants provided written informed consent prior to receiving the FAc injection. This study adhered to Good Clinical Practice\/International Council for Harmonization Guidelines, the Declaration of Helsinki, and all applicable country-specific regulations governing clinical research, prioritizing whichever provided greater protection to the individual. Any information that could identify an individual has been encrypted or removed to ensure anonymity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}